News Focus
News Focus
Post# of 257253
Next 10
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 112548

Friday, 01/14/2011 12:48:08 PM

Friday, January 14, 2011 12:48:08 PM

Post# of 257253
The primary beneficiary of ABT’s mishap with Briakinumab is JNJ’s Stelara, which has been a commercial disappointment to date.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now